Pompe Disease Treatment Market Overview, Therapy Analysis, Challenges and Industry Forecast to 2025
Market Highlights:
The global Pompe Disease Treatment Market is estimated to be valued at USD 1,414.1 million by 2025 and is expected to register a CAGR of 2.6% during the forecast period.
Pompe disease is a
disorder affecting almost 1 in 40,000 people in the US. Factors such as
constant uptake of long-term therapies, high cost of treatment, and launch of
novel drugs are boosting the market
growth. It is an autosomal recessive glycogen storage disorder and occurs due
to deficiency of lysosomal enzyme acid α-glucosidase (GAA). The juvenile or
adult-onset form and is reported to be the most
common form in almost 80% of patients. This disorder primarily affects cardiac
and skeletal muscle and manifests as progressive respiratory distress, skeletal
muscles atrophy, and cardiomyopathy.
Access
Full Report Details and TOC Exclusively @ https://www.marketresearchfuture.com/reports/pompe-disease-treatment-market-8233
Major Players:
·
Audentes Therapeutics
·
CENTOGENE AG,
·
Oxyrane
·
Amicus Therapeutics
·
Genzyme Corporation
·
Valerion Therapeutics
·
AVROBIO
Segment Analysis
·
The global Pompe disease
treatment market by type has been segmented into onset Pompe disease,
non-classic infantile-onset Pompe disease, and classic infantile-onset Pompe
disease. Late-onset Pompe disease, a heterogeneous form of the disease, causes
various problems related to musculoskeletal, neuromuscular, respiratory, and
cardiac functioning. Late-onset Pompe disease mainly appears during teenage or
adulthood.
·
The treatment of Pompe
disease is disease-specific and depends on the symptoms of the disease. The
global Pompe disease treatment market on the basis of therapy has been divided
into, enzyme replacement therapy (ERT), gene therapy, and others. The enzyme
replacement therapy (ERT) segment captures the maximum share of the total
market as it is the only Food and Drug Administration (FDA) approved therapy
for the treatment of Pompe diseases.
·
The Pompe disease
treatment market has been classified, on the basis of end user, as hospitals &
clinics and research & academic institutes.
Regional Analysis
The global Pompe disease
treatment market, based on region, has been categorized as the Americas,
Europe, Asia-Pacific, and the Middle East & Africa.
American regions are hubs
for major market players operating in the Pompe disease treatment market, which
eventually drives the growth of the American Pompe disease treatment market.
Additionally, the rising awareness among the public about the available
treatments for Pompe disease is projected to boost the market growth in America
during the forecast period.
Europe stands second in
the global Pompe disease treatment market followed by Asia-Pacific. European
countries are extremely cautious and have implemented the new-born screening
(NBS) program as a means of early detection and identification of severe
illnesses in new-borns.
Asia-Pacific is
anticipated to be the fastest-growing
region in the global Pompe disease treatment market during the forecast period.
This growth is affected by factors such as rising healthcare expenditures,
increasing awareness among patients regarding rare disorders, and improved
healthcare.
The Middle East &
Africa accounted for a relatively smaller market share in 2018 due to low per
capita income and lack of adequate healthcare infrastructure support.
Related Reports
·
Global
Cystic Fibrosis Market: Information by Treatment Method (Medication, Devices, and
Others) and Region (North America, Europe, Asia-Pacific, and the Middle East
& Africa)—Forecast till 2025
·
Hemophilia
Treatment Market Research Report: Information by Type (Hemophilia A, Hemophilia
B, and Hemophilia C), By Treatment (Recombinant Coagulation Factor,
Plasma-Derived Coagulation Factor, and Desmopressin, Antifibrinolytic Agents), and
End User—Global Forecast Till 2023
Comments
Post a Comment